Tuesday, Jan. 24, 2017
A new national drug program will bring additional costs to taxpayers, and therefore does nothing to change the incentives which encourage governments to restrict access to the most expensive new drugs in the first place.
Governments should end existing public programs and enact policies that would encourage the emergence of a competitive private-sector insurance market in which universal access to catastrophic drug insurance could be facilitated through means-tested subsi
Sent to you every weekday morning. SIGN UP.
© 2017 Hill Times Publishing |
Contact Us |
Work with Us |